SPRY
ARS Pharmaceuticals, Inc
4.20$
-6.7%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -197.0% | – | – | – | – | – | – | |
| – | -42.9% | -8.3% | +63.6% | +16.7% | -7,314.3% | – | – | +743.0% | -165.6% | – | +4.8% | – | |
| – | -12.7% | +45.5% | +1.5% | +6.7% | +18.7% | +24.3% | +1.4% | +5.9% | +0.8% | +29.4% | +67.0% | – | |
| – | -1,142.6% | – | +68.1% | -139.0% | – | – | – | – | – | – | -249.3% | – | |
| – | +111.6% | -8.8% | -54.2% | +268.4% | +115.7% | -69.9% | -44.0% | +286.3% | -100.0% | – | – | – | |
| – | – | -132.7% | +48.5% | – | -705.1% | – | +67.1% | -192.6% | – | +15.2% | +49.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +96.0% | -85.7% | +111.2% | +24.8% | +10,328.8% | -99.0% | +272.0% | +3,609.5% | -98.9% | -85.9% | +1,910.7% | – | |
| – | – | -243.4% | – | – | +268.2% | -198.1% | – | -31.3% | -327.5% | – | – | – | |
| – | – | – | – | – | – | -197.9% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.